U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT07444983) titled 'Rezvilutamide for High-Risk Prostate Cancer After Surgery' on Feb. 24.
Brief Summary: The goal of this clinical trial is to learn if Rezvilutamide works to treat high-risk prostate cancer in patients who have recently undergone surgery (radical prostatectomy). It will also learn about the safety of Rezvilutamide. The main questions it aims to answer are:
Does Rezvilutamide, when used as an add-on treatment after surgery, lower the risk of the cancer returning (biochemical recurrence) within 3 years? What is the 36-month metastasis-free survival (MFS) rate for patients receiving this treatment? What is the safety profile of Rezvilut...